AbdullGaffar B.,Dubai Hospital
Southern Medical Journal | Year: 2010
Objectives: Gastrointestinal stromal tumor (GIST) is a relatively uncommon and predominantly sporadic tumor of the gastrointestinal tract (GIT). Infrequently, it can be associated with other neoplasms, notably GIT carcinomas and, rarely, extra-gastrointestinal tumors. Whether this concomitant occurrence is a causal association or a coincidence is not yet resolved, nor is its clinical importance determined. We attempted to investigate the frequency and spectrum of associations between non-incidental GISTs and extra-GIT tumors. Methods: A retrospective review study was carried out over 18 years of records. All confirmed cases of GISTs were retrieved from the pathology files of our institution. Each case was investigated for any synchronous or metachronous association with GIT or extra- GIT tumors. Results: Five (24%) out of 21 cases of GISTs were found to be either synchronously or metachronously associated with extra-gastrointestinal neoplasms in 55% of the women with GISTs. Males had no such association. Conclusion: The cause of the association between non-incidental GISTs and extra-GIT tumors is difficult to determine. In the majority of cases, this association is most likely a coincidental finding. Synchronous occurrence with certain tumors, however, may suggest a nonrandom causal association. We report a case series study of the possible association of GISTs with extra-GIT tumors in female patients. Like other studies, we suggest that patients - especially women - with GISTs should be clinically investigated and followed up for the possibility of coexisting GIT and extra-GIT neoplasms. Copyright © 2010 by The Southern Medical Association.
Dawood S.,Dubai Hospital
Expert Review of Molecular Diagnostics | Year: 2010
Once metastatic disease is documented, cure is no longer the goal and the disease is generally associated with poor outcomes, with the majority of patients dying of their disease rather than other causes. The last three decades have seen significant advances in the genomics, proteomics and molecular pathology of biomarkers in cancer, allowing for individualization of therapy that has significantly and positively impacted survival outcomes. Genetic signatures have been identified that can predict not only the future development of metastases, but also the development of specific sites of metastases. Protein biomarkers have been identified that are in use clinically for the monitoring of both disease progression and therapeutic efficacy. DNA- and RNA-based biomarkers have also been identified. This review will focus on some of the novel biomarkers that have been developed over the last decade. © 2010 Expert Reviews Ltd.
Scaltriti M.,Massachusetts General Hospital |
Scaltriti M.,Harvard University |
Dawood S.,Dubai Hospital |
Cortes J.,Vall dHebron Institute of Oncology VHIO
Clinical Cancer Research | Year: 2012
Many kinases and hormone receptors, important for cancer cell proliferation and survival, bind to and are dependent on the Hsp90 cycle for their folding and maturation. This provides the rationale for the development of small-molecule ATP competitors that, inhibiting Hsp90 function, lead to degradation of the "client" proteins. After continual efforts to improve the pharmacologic properties and the tolerability of these molecules, several Hsp90 inhibitors have exhibited activity in both preclinical models and in the clinical setting. As is the case with many other targeted agents, patient selection seems to be the major limitation to the success of these compounds. ERBB2-positive patients with breast cancer are exquisitely sensitive to Hsp90 inhibition. This is because ERBB2 is indispensable for growth and survival of this subtype of cancer, and at the same time ERBB2 is a client protein strictly dependent on Hsp90 for its maturation and stability. Extensive preclinical work identifying other ERBB-like client proteins will likely lead to the ability to enhance selection of appropriate patients for enrollment in more rational clinical trials. Hsp90 inhibition has also been reported to synergize with other therapeutic agents. Several ongoing studies testing different combinations of Hsp90 inhibitors with other targeted agents will confirm whether Hsp90 inhibition can potentiate the efficacy of targeted therapy and/or prevent the emergence of drug resistance. ©2012 AACR.
Dawood S.,Dubai Hospital |
Cristofanilli M.,Fox Chase Cancer Center
Oncology | Year: 2011
Inflammatory breast cancer (IBC) is a rare and aggressive subtype of locally advanced breast cancer (LABC). Its diagnosis is primarily clinical; however, a pathological confirmation of invasive cancer is required. Historically, IBC was a uniformly fatal disease. A major advance in the last three decades has been the introduction of a multidisciplinary approach to the management of this aggressive disease, incorporating pre-operative chemotherapy, surgery, and radiation therapy; this approach has significantly improved survival. Our review focuses on the progress made in the field of IBC research over the last decade, with particular attention to advances in the areas of epidemiology, molecular biology, and clinical management.
Abdullgaffar B.,Dubai Hospital
Cytopathology | Year: 2012
Objective: To study the trends of impact factor (IF) in four cytopathology journals. To investigate the factors that might influence IF in cytopathology literature and whether IF has any impact on cytopathology practice. Methods: The IFs of four cytopathology journals were searched from 2005 to 2009. The IFs and their relationships with the types and number of publications, publishers, the official societies, readership, the quality of their contents, the topics covered and the levels of evidence were compared. Results: Cancer Cytopathology (CC) had the highest IF. Acta Cytologica (AC) had the lowest IF, which appeared to be in decline. Cytopathology (C) and Diagnostic Cytopathology (DC) had a slow but steady increase in their IF. Components that might influence these differences could include the category and the society of the journal, targeted readers and certain types of publications. Publishers, the number of publications, the types of topics covered and the levels of evidence probably have no major effect on IF. Conclusions: IF has its own benefits and original applications. IF is a quantitative measure that does not reflect the levels of evidence in cytopathology journals. IF should not be abandoned because it might encourage competition between cytopathology journals, but it should not dictate their contents. © 2012 Blackwell Publishing Ltd.